AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03955497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-derived Mesenchymal Stem Cell Gel
Description: The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
Study NCT03955497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hyaluronate
Description: The control group received intra-articular injection of sodium hyaluronate one month after operation.
Study NCT03955497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of abdominal fat
Description: In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel.
Study NCT03185468 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 4SCAR-PSMA
Description: PSMA-specific 4th Generation CART
Study NCT03185468 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 4SCAR-FRa
Description: FRa-specific 4th Generation CART
Study NCT02947490 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self BP measurement
Description: BP home measurement by patient, results to GP and GP alters treatment as per usual practice
Study NCT02947490 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
Study NCT02947490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
Study NCT02947490 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard BP management
Description: GP to measure BP and manage BP control
Study NCT02947490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
Study NCT02959970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel
Description: Dapsone (ACZONE) 7.5% gel topically once daily.
Study NCT02027974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iconacy Hip System
Description: Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
Study NCT02027974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Accolade Hip System
Description: Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
Study NCT02791867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AphoelineBrake
Description: The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
Study NCT02791867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AphoelineBrake
Description: The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
Study NCT01391468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
Study NCT01391468 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch
Description: placebo will be given in 6 months
Study NCT03207724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xilonix plus Onivyde and 5FU
Description: Xilonix by IV
Study NCT03444467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1513
Description: Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.
Study NCT03444467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Participants will receive single dose of 1 mg glucagon s.c. injection.
Study NCT03444467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive single dose of placebo (for double dummy injections).
Study NCT03444467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single dose of placebo (for double dummy injections).
Study NCT00095810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Tablets, Oral, 1-10mg, Once daily, 6 weeks.
Study NCT04371185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2206
Description: 45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
Study NCT04371185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara(US-licensed)
Description: 45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
Study NCT04371185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara(EU-licensed)
Description: 45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
Study NCT01025297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: 3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
Study NCT02715596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA supplementation
Description: 2.7 g EPA supplementation in a 15 cc emulsion stick-pack
Study NCT02715596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo in 15 cc emulsion stick-pack
Study NCT03582969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal transplantation
Description: Fecal transplantation administered orally via frozen capsules.
Study NCT03582969 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT01851525 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermoCoolSmartTouch ablation catheter, Biosense Webster
Study NCT00656578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975
Description: Single dose, solution
Study NCT00656578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, solution
Study NCT02100410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T1
Description: Iteration 2-87-1 with embossed mark
Study NCT02100410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T2
Description: Iteration 2-87-1 without embossed mark
Study NCT02100410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T3
Description: Iteration 2-87-2 with embossed mark
Study NCT02100410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T4
Description: Iteration 2-87-2 without embossed mark
Study NCT02100410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T5
Description: Iteration 2-87-3 with embossed mark
Study NCT02100410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A toric contact lens T6
Description: Iteration 2-87-3 without embossed mark
Study NCT03904576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet
Study NCT03904576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT02106104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg QD (N=24)
Description: Linagliptin 5 mg will be taken orally, once daily for 8 weeks
Study NCT02106104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1 mg QD (N=24)
Description: Glimepiride 1 mg will be taken orally, once daily for 8 weeks
Study NCT00516958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Dermacyn
Description: Topical Dermacyn once a day for 10 Days
Study NCT00516958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Dermacyn and Levofloxacin
Description: Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
Study NCT00516958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Saline and Levofloxacin
Description: Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
Study NCT02622438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Followed with an initial assessment, six months and followed annually for 3 years corresponding to the usual follow-up of the patient.
Study NCT03503812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (1) for outdoor exposure reduction - Asthma in Children
Description: Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity
Study NCT03503812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children
Description: Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' schools and houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners.
Study NCT03503812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (1) for outdoor exposure reduction - Atrial Fibrillation
Description: Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity
Study NCT03503812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation
Description: Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the follow-up period. This intervention will consist of two recommendations:~1. Reduce time spent outdoors and~2. Reduce physical activity~   ii) indoor particle levels on a continuous daily basis throughout the follow-up DDS period. This intervention will consist of two recommendations for participants' houses:~3. Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~4. Reduce indoor particle levels by using air cleaners.
Study NCT03043261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Williams LifeSkills
Description: Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
Study NCT04536493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)
Description: 1 application of LET topical anesthetic gel
Study NCT04536493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)
Description: 3 applications of LET topical anesthetic gel
Study NCT03193450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based re-education
Description: Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
Study NCT03193450 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First education at the clinic
Description: Patients will receive an instruction card about the drug administration at the clinic by doctors.
Study NCT03193450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First education at the clinic
Description: Patients will receive an instruction card about the drug administration at the clinic by doctors.
Study NCT01911208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECRUIT intervention
Description: Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
Study NCT01911208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Non-intervention control.
Study NCT04216706 — intervention group
Intervention type: DRUG
Intervention: tailored pharmaceutical treatment
Description: Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
Study NCT03273231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
Study NCT03273231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% saline solution
Study NCT01402388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group lifestyle programme
Study NCT03081572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet aggregation
Description: Platelet aggregation
Study NCT01522560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback group
Description: Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF).
Study NCT01522560 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
Study NCT00260195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based cognitive behavioral support group
Study NCT02457299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two Stage Esophagectomy
Description: Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
Study NCT02457299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One Stage Esophagectomy
Description: Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
Study NCT03023605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Intervention for PE Diagnosis
Description: Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:~1. Clinical Update Sessions for staff ED (20 physicians)~2. training sessions for residents that rotate in ED (60 physicians )~3. Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value~4. Development of posters, with brief information~5. Dissemination by e-mail of scientific information~6. Direct reminder during the working day
Study NCT01989572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00442039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
Study NCT03555331 — intervention group
Intervention type: BEHAVIORAL
Intervention: Child Safety Control Intervention
Description: In the study period which spanned from early infancy through age 3 years, the child safety intervention group was given an educational program with messages focused on child and home safety, guided by the American Academy of Pediatrics and the Academy's guide for health supervision, Bright Futures. The observation-only study extension will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
Study NCT03555331 — intervention group
Intervention type: BEHAVIORAL
Intervention: Responsive Parenting Intervention
Description: During infancy, the Responsive Parenting group was given an educational program containing messages providing developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle aimed at preventing rapid weight gain in infancy and overweight at age 3 years. The new study period will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
Study NCT03052127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light-activated AU-011
Description: Study treatment
Study NCT01989572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01989572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given GM-CSF placebo SC
Study NCT03052127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Activation
Description: Study treatment
Study NCT01989572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given GM-CSF placebo SC
Study NCT01989572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given peptide placebo SC
Study NCT01989572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given peptide placebo SC
Study NCT01989572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT02368574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Class II hysterectomy
Description: Class II hysterectomy
Study NCT02166814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan and Rosuvastatin
Study NCT02166814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Study NCT02166814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Study NCT03552835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no caries removal
Description: occlusal caries were treated with no caries removal and placement of stainless steel crown
Study NCT03552835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal upto soft dentin
Description: occlusal caries were treated by partial caries removal upto soft dentin followed by Glass Ionomer Cement placement as a base and composite restoration
Study NCT03552835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial caries removal upto firm dentin
Description: occlusal caries were treated by partial caries removal upto firm dentin followed by Glass Ionomer Cement placement as a base and composite restoration
Study NCT00642681 — intervention group
Intervention type: DRUG
Intervention: Technosphere Insulin
Description: Technosphere® Insulin (TI) Inhalation Powder, prandial